ArticleAnnals of medicine and surgery (2012)2025
Impact of IDH mutation and adjuvant chemo(radio)therapy on survival outcome in grade II/III astrocytoma: a retrospective cohort study based on SEER database.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06620926 (Impact of IDH Mutation and Adjuvant Chemo), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Astrocytoma is a primary brain tumor arising from specific glial cells called astrocytes. Isocitrate dehydrogenase (IDH) mutations represent an early oncogenic event in glioma evolution. The 2-hydroxyglutarate builds up and is produced in grade II/III astrocytoma. Adjuvant chemo(radio)therapy is the standard treatment. Optimal treatment strategies are controversial due to the risk-benefit ratio. This study aimed to assess the effect of IDH mutation on the survival outcome with different treatment modalities for better understanding of the disease. Methods: Data were obtained from the SEER program for patients with diffuse and anaplastic astrocytoma diagnosed from 2018 to 2020. Patients were divided into wild-type (wIDH) and mutant-type (mIDH) groups and subclassified based on the received adjuvant therapy (chemotherapy, radiotherapy, chemoradiotherapy). All patients had surgery (tumor destruction, local excision, partial, radial, and total gross resection). SPSS 27 was used for statistical analysis, Kaplan-Meier curve, and Long-Rank test for survival analysis. Results: Out of 811 patients, 486 (59.9%) had mIDH, and 325 (40.1%) had wIDH. The 2-year relative survival for mIDH was 95% and 51% for wIDH, Conclusions: The mIDH had better 2-year relative survival compared to wIDH across all treatment modalities. Adjuvant chemotherapy had more than 20% survival benefit compared to radiotherapy in mIDH and wIDH. These results highlight adjuvant chemotherapy as the modality of choice for mIDH to improve the survival outcome and avoid radiotherapy's unfavorable side effects. The study was registered at Clinicaltrial.gov with identification number of NCT06620926.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.